Tech Company Financing Transactions
Tissium Funding Round
On 6/24/2026, Tissium received $68 million in Series D funding from Cathay Health, European Investment Bank and Merieux Developpement.
Transaction Overview
Company Name
Announced On
6/24/2026
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$68,000,000
Round
Series D
Proceeds Purpose
The funding will be used to finance the rolling out of its tech in the US, and fund clinical trials as it looks to expand the tech to other areas of healthcare.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
74 rue du Faubourg Saint-Antoine
Paris, 75012
FR
Paris, 75012
FR
Phone
Website
Email Address
Overview
TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christophe Bancel
Chief Financial Officer
Romain Attard
Co-Founder
Maria Pereira
Browse more venture capital transactions:
Prev: 6/24/2026: Coval venture capital transaction
Next: 6/24/2026: Valence AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs